000128518 001__ 128518
000128518 005__ 20240228135104.0
000128518 0247_ $$2doi$$a10.1182/blood-2013-12-538975
000128518 0247_ $$2pmid$$apmid:24916506
000128518 0247_ $$2ISSN$$a0006-4971
000128518 0247_ $$2ISSN$$a1528-0020
000128518 037__ $$aDKFZ-2017-04534
000128518 041__ $$aeng
000128518 082__ $$a610
000128518 1001_ $$aWeisser, Martin$$b0
000128518 245__ $$aPTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
000128518 260__ $$aStanford, Calif.$$bHighWire Press$$c2014
000128518 3367_ $$2DRIVER$$aarticle
000128518 3367_ $$2DataCite$$aOutput Types/Journal article
000128518 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1523618544_30814
000128518 3367_ $$2BibTeX$$aARTICLE
000128518 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128518 3367_ $$00$$2EndNote$$aJournal Article
000128518 520__ $$aAddition of rituximab (R) to fludarabine and cyclophosphamide (FC) has significantly improved patient outcomes in chronic lymphocytic leukemia (CLL). Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined. We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH, a study of FC or R-FC in relapsed CLL. An independent test set was derived from 282 pretreatment specimens from CLL8, a study of FC or R-FC in treatment-naïve patients. Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models. REACH patients with higher pretreatment protein tyrosine kinase 2 (PTK2) messenger RNA levels derived greater benefit from R-FC, with significant improvements in progression-free survival, independent of known prognostic factors in a multivariate model. Examination of PTK2 gene expression in CLL8 patients yielded similar results. Furthermore, PTK2 inhibition blunted R-dependent cell death in vitro. This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC. PTK2 expression may be a useful biomarker for patient selection in future trials. These trials were registered at www.clinicaltrials.gov as #NCT00090051 (REACH) and #NCT00281918 (CLL8).
000128518 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000128518 588__ $$aDataset connected to CrossRef, PubMed,
000128518 650_7 $$2NLM Chemicals$$aAntibodies, Monoclonal, Murine-Derived
000128518 650_7 $$2NLM Chemicals$$aRNA, Messenger
000128518 650_7 $$2NLM Chemicals$$aRNA, Neoplasm
000128518 650_7 $$04F4X42SYQ6$$2NLM Chemicals$$aRituximab
000128518 650_7 $$08N3DW7272P$$2NLM Chemicals$$aCyclophosphamide
000128518 650_7 $$0EC 2.7.10.2$$2NLM Chemicals$$aFocal Adhesion Kinase 1
000128518 650_7 $$0EC 2.7.10.2$$2NLM Chemicals$$aPTK2 protein, human
000128518 650_7 $$0FA2DM6879K$$2NLM Chemicals$$aVidarabine
000128518 650_7 $$0P2K93U8740$$2NLM Chemicals$$afludarabine
000128518 7001_ $$aYeh, Ru-Fang$$b1
000128518 7001_ $$aDuchateau-Nguyen, Guillemette$$b2
000128518 7001_ $$aPalermo, Giuseppe$$b3
000128518 7001_ $$00000-0002-6769-8664$$aNguyen, Tri Quang$$b4
000128518 7001_ $$aShi, Xiaoyan$$b5
000128518 7001_ $$aStinson, Susanna Y$$b6
000128518 7001_ $$aYu, Nancy$$b7
000128518 7001_ $$aDufour, Annika$$b8
000128518 7001_ $$aRobak, Tadeusz$$b9
000128518 7001_ $$aSalogub, Galina N$$b10
000128518 7001_ $$aDmoszynska, Anna$$b11
000128518 7001_ $$aSolal-Celigny, Philippe$$b12
000128518 7001_ $$aWarzocha, Krzysztof$$b13
000128518 7001_ $$aLoscertales, Javier$$b14
000128518 7001_ $$aCatalano, John$$b15
000128518 7001_ $$aLarratt, Loree$$b16
000128518 7001_ $$aRossiev, Viktor A$$b17
000128518 7001_ $$aBence-Bruckler, Isabelle$$b18
000128518 7001_ $$aGeisler, Christian H$$b19
000128518 7001_ $$aMontillo, Marco$$b20
000128518 7001_ $$aFischer, Kirsten$$b21
000128518 7001_ $$aFink, Anna-Maria$$b22
000128518 7001_ $$aHallek, Michael$$b23
000128518 7001_ $$aBloehdorn, Johannes$$b24
000128518 7001_ $$aBusch, Raymonde$$b25
000128518 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b26$$udkfz
000128518 7001_ $$aDöhner, Hartmut$$b27
000128518 7001_ $$aValente, Nancy$$b28
000128518 7001_ $$aWenger, Michael K$$b29
000128518 7001_ $$aStilgenbauer, Stephan$$b30
000128518 7001_ $$aDornan, David$$b31
000128518 773__ $$0PERI:(DE-600)1468538-3$$a10.1182/blood-2013-12-538975$$gVol. 124, no. 3, p. 420 - 425$$n3$$p420 - 425$$tBlood$$v124$$x1528-0020$$y2014
000128518 909CO $$ooai:inrepo02.dkfz.de:128518$$pVDB
000128518 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b26$$kDKFZ
000128518 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000128518 9141_ $$y2014
000128518 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD : 2015
000128518 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128518 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128518 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128518 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128518 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128518 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128518 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128518 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128518 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128518 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128518 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128518 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128518 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bBLOOD : 2015
000128518 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000128518 980__ $$ajournal
000128518 980__ $$aVDB
000128518 980__ $$aI:(DE-He78)C060-20160331
000128518 980__ $$aUNRESTRICTED